Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2009-03-04
2011-11-01
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S344000, C514S971000, C424S449000, C424S444000
Reexamination Certificate
active
08048927
ABSTRACT:
The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.
REFERENCES:
patent: 4919937 (1990-04-01), Mauvais-Jarvis et al.
patent: 4973755 (1990-11-01), Grafe et al.
patent: 5045553 (1991-09-01), Ueda et al.
patent: 5613958 (1997-03-01), Kochinke et al.
patent: 5720963 (1998-02-01), Smith
patent: 5904930 (1999-05-01), Fischer et al.
patent: 6013270 (2000-01-01), Hargraves et al.
patent: 6503894 (2003-01-01), Dudley et al.
patent: 6632841 (2003-10-01), Af Ursin et al.
patent: 7485623 (2009-02-01), Bua
patent: 7507769 (2009-03-01), Nestour
patent: 7704516 (2010-04-01), Drouin et al.
patent: 7767717 (2010-08-01), Palumbo et al.
patent: 2001/0041718 (2001-11-01), Thompson et al.
patent: 2003/0017539 (2003-01-01), Glucksmann et al.
patent: 2003/0087885 (2003-05-01), Masini-Eteve et al.
patent: 2003/0175329 (2003-09-01), Azarnoff et al.
patent: 2004/0018991 (2004-01-01), Schmidt et al.
patent: 2004/0086552 (2004-05-01), Klokkers et al.
patent: 2004/0138314 (2004-07-01), Bua
patent: 2005/0031695 (2005-02-01), Rouanet et al.
patent: 2005/0032909 (2005-02-01), Lignieres et al.
patent: 2005/0032910 (2005-02-01), Palumbo et al.
patent: 2005/0158388 (2005-07-01), Le Nestour et al.
patent: 2005/0208139 (2005-09-01), Hilt et al.
patent: 2006/0105041 (2006-05-01), Masini-Eteve
patent: 2009/0186944 (2009-07-01), Rouanet et al.
patent: 32 38 984 (1983-05-01), None
patent: 38 36 862 (1990-05-01), None
patent: 0 513 832 (1992-11-01), None
patent: 1 579 856 (2005-09-01), None
patent: 1 579 857 (2005-09-01), None
patent: WO 99/33451 (1999-07-01), None
patent: WO 01/43775 (2001-06-01), None
patent: WO 2004/054557 (2004-07-01), None
patent: WO 2004/054558 (2004-07-01), None
patent: WO 2004/087123 (2004-10-01), None
Wechter, MedlinePlus Medical Encyclopedia, “fibrocystic breast disease”, Dec. 17, 2009 (3 pages).
Kang et al. Arch Pathol. Lab Med 125(2001).
J. Barrat et al., “Effet in vivo de l'administration locale de progestérone sur l'activité mitotique des galactophores humains”, J. Gynecol. Obstet. Biol. Reprod. 19: 269-274 1990.
Bronaugh & Maibach, “Percutaneous Absorption Drugs-Cosmetics-Mechanisms-Methodology”, Marcel Dekker Inc., New York, 1999.
Philip Carthew et al., “Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat”, Arch Toxicol (2001) 75: 375-380.
Gerard Chetrite et al., “Effect of Promegestone, Tamoxifen, 4-Hydroxytamoxifen and ICI 164,384 on the Oestrone Sulphatase Activity of Human Breast Cancer Cells”, Anticancer Research 13: 931-934 (1993).
Eric C. Dietze et al., “Tamoxifen but Not 4-Hydroxytamoxifen Initiates Apoptosis in p53(−) Normal Human Mammary Epithelial Cells by Inducing Mitochondrial Depolarization”, The Journal of Biological Chemistry vol. 276, No. 7, Issue of Feb. 16, 2001, pp. 5384-5394.
Ian S. Fentiman, “Tamoxifen and Mastalgia an Emerging Indication”, Drugs, vol. 32, No. 6, Dec. 1986, pp. 477-480.
I.S. Fentiman et al., “Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial”, Br. J. Surg. Sep. 1988, vol. 75, No. 9, pp. 845-846.
I.S. Fentiman et al., “Studies of tamoxifen in women with mastalgia*”, The British Journal of Clinical Practice, Supplement 68, vol. 43, No. 11, Nov. 1989, pp. 34-36.
N. Giambiagi et al., “Immunological Differences Between the Estradiol-, Tamxifen- and 4-Hydroxy-Tamoxifen-Estrogen Receptor Complexes Detected by Two Monoclonal Antibodies”, J. Steroid Biochem. vol. 30, No. 1-6, pp. 213-217, 1988.
V. Craig Jordan et al., “Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance”, Breast Cancer Research and Treatment, 2, pp. 123-138.
George G.J.M. Kuiper et al., “Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β”, Endocrinology, vol. 138, No. 3, 1997, pp. 863-870.
Frédérique Kuttenn et al., “Médecine Et Thérapeutique”, C.R. Acad. Sc. Paris, , Série III, No. 12, 1985, 300:457-461.
Catherine Malet et al., “Tamoxifen and Hydroxytamoxifen IsomersversusEstradiol Effects on Normal Human Breast Cells in Culture”, Cancer Research, vol. 48, No. 24, Dec. 15, 1988, pp. 7193-7199.
Pierre Mauvais-Jarvis et al., “trans-4-Hydroxytamoxifen Concentration and Metabolism after Local Percutaneous Adminstration to Human Breast”, Cancer Research, vol. 46, Mar. 1986, pp. 1521-1525.
Henri Pujol et al., “Phase I Study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue”, Cancer Chemother. Pharmacol., 36:493-498 (1995).
David W. Robertson et al., “Synthesis of theEandZIsomers of the Antiestrogen Tamoxifen and Its Metabolite, Hydroxytamoxifen, in Tritium-Labeled Form”, J. Org. Chem., 1982, vol. 47, No. 12, pp. 2387-2393.
David W. Robertson et al., “Tamoxifen Antiestrogens, A Comparison of the Activity, Pharmacokinetics, and Metabolic Activation of theCISandTransIsomers of Tamoxifen” Journal of Steroid Biochemistry, vol. 16, pp. 1-13, (1982).
Fabrice Sauvez et al., “Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats”, Carcinogenesis vol. 20, No. 5, pp. 843-850 1999.
John N. Wolfe MD, “Risk for Breast Cancer Development Determined by Mammographic Parenchymal Pattern”, Cancer, May 1976, vol. 37, No. 5, pp. 2486-2492.
Carol A. Bodian Dr.P.H., et al., “Prognostic Significance of Benign Proliferative Breast Disease”, Cancer, Jun. 15, 1993, vol. 71, No. 12, pp. 3896-3907.
Christine L. Carter et al., “A Prospective Study of the Development of Breast Cancer in 16,692 Women with Benign Breast Disease”, American Journal of Epidemiology, vol. 128, No. 3, Sep. 1988, pp. 467-477.
William D. Dupont Ph.D. et al., “Risk Factors for Breast Cancer in Women With Proliferative Breast Disease”, The New England Journal of Medicine, vol. 312, No. 3, Jan. 1985, pp. 146-151.
William D. Dupont Ph.D. et al., “Long-Term Risk of Breast Cancer in Women with Fibroadenoma”, The New England Journal of Medicine, vol. 331, No. 1, Jul. 1994, pp. 10-15.
Patrick L. Fitzgibbons, MD. et al., “Benign Breast Changes and the Risk for Subsequent Breast Cancer”, Arch. Pathol. Lab. Med. vol. 122, Dec. 1998, pp. 1053-1055.
Stanley G. Korenman et al., “Estradiol Radioimmunoassay Without Chromatography: Procedure, Validation and Normal Values”, J. Clin. Endocrinol. Metab. 38, pp. 718-720, 1974.
Nancy Krieger et al., “Risk of Breast Cancer after Benign Breast Diseases Variation by Histologic Type, Degree of Atypia, Age at Biopsy, and Length of Follow Up”, American Journal of Epidemiology, vol. 135, No. 6, pp. 619-631, Mar. 1992.
Kyung-Hoon Lee et al., “Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial”, Journal of Chromatography B., 791 (2003), pp. 245-253.
Mizuki Nishino et al., “Effects of Tamoxifen on Hepatic Fat Content and the Development of Hepatic Steatosis in Patients with Breast Cancer; High Frequency of Involvement and Rapid Reversal After Completion of TAmoxifen Therapy”, AJR: 180, Jan. 2003, pp. 129-134.
Lawrence H. Block PhD “Epidermal and Transdermal Drug Delivery”, The Science and Practice of Pharmacy, Medicated Topicals, pp. 836-857 (2000).
Asher Shushan
Besins Healthcare Luxembourg
Fetterolf Brandon
Foley & Lardner LLP
Gembeh Shirley V
LandOfFree
Treatment and prevention of benign breast disease with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of benign breast disease with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of benign breast disease with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4285704